Arrowhead Pharma Analyst Price Targets

Arrowhead Pharmaceuticals Inc

ARWRNASDAQ

Trade with Public

$57.23

1.332.38%

Últ. Act.: Oct 19, 5:42 PM

$57.50

1.602.86%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Arrowhead Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arrowhead Pharma (ARWR).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

12Buy

3Hold

Consensus RatingBuy# Analysts15Avg. Consensus PT$89Upside to Avg. PT+55.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	UBS	John Lee	Assumes	Buy	$63→$109
Oct 15, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$115
Oct 15, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$120
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Neutral	$74
Sep 8, 2026	Citigroup	Eric Joseph	Initiate	Buy	$108
Sep 1, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$120
Aug 31, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$115
Aug 31, 2026	RBC Capital	Luca Issi	Maintained	Outperform	$100
Aug 6, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$115→$120
Jul 30, 2026	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$101→$123
Jul 27, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$100→$115
Jul 23, 2026	Morgan Stanley	Michael Ulz	PT Raise	Overweight	$100→$120
Jul 23, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$110→$126
Jul 22, 2026	Chardan Capital	Keay Nakae	PT Raise	Buy	$90→$115
Jul 17, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$88→$95
Jul 14, 2026	Stifel	James Condulis	Initiate	Buy	$98
Jul 1, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$100
Jun 30, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$90
Jun 17, 2026	Leerink Partners	Mani Foroohar	PT Raise	Market Perform	$61→$72
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$35→$46

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Arrowhead Pharma (NASDAQ:ARWR) with a Neutral and announces $74 price target.

Benzinga Newsdesk

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

Citigroup analyst Eric Joseph initiates coverage on Arrowhead Pharma (NASDAQ:ARWR) with a Buy rating and announces Price Target of $108.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $120 price target.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

RBC Capital analyst Luca Issi reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Outperform and maintains $100 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.

Benzinga Newsdesk

Arrowhead Pharmaceuticals Inc

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

Arrowhead Pharmaceuticals Inc

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PROGoldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PROCitigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRORBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PROHC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Arrowhead Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PROGoldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PROCitigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PROHC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRORBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PROHC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target

PRO
Citigroup Initiates Coverage On Arrowhead Pharma with Buy Rating, Announces Price Target of $108

PRO
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $120 Price Target

PRO
RBC Capital Reiterates Outperform on Arrowhead Pharma, Maintains $100 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120